Recombinant tissue plasminogen activator (rt-PA) is the only US F

Recombinant tissue plasminogen activator (rt-PA) is the only US FDA (United States Food and Drug Administration) approved treatment, focuses on recanalization to reduce the size of ischemic damage.11 and 12 So far, numerous attempts have been made to find the best among the various therapeutic interventions such as ischemic preconditioning, controlled reperfusion and antioxidant, complement or neutrophil therapy.13 Therefore, it is still essential to search for new class of neuroprotective strategies which may perhaps significantly prevent or limit I/R injury in humans. Currently both experimental and epidemiological

evidences demonstrate that 2,4,6-trisubstituted-1,3,5-pyrimidines have received much attention of researchers because selleck kinase inhibitor of their cerebroprotective actions.14, 15, 16 and 17 Hence in the present investigation it was proposed worthwhile to study the possible inherent mechanisms behind their cerebroprotection by targeting oxidation and inflammation pathways in global ischemia-reperfusion induced cerebral infarction in rats. Thiopentone sodium, 2,3,4-tetrazolium chloride, Thiobarbituric acid, 1,1,3,3-tetraethoxy-propane,

nitroblue tetrazolium, Nicotinamide adenine dinucleotide phosphate reduced form, 2,4,6-trisubstituted-1,3,5-pyrimidines (AUCP1 and AUCP2) were procured from Pharmaceutical Chemistry Research Laboratories, Afatinib Andhra University as gift samples (Fig. 1). All experimental protocols were approved by the Institutional Animal Ethics Committee of AU College of Pharmaceutical Sciences, Andhra University vide proposal no: (Approval No. 516/01/A/CPCSEA) under the regulation of Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), SB-3CT New Delhi. Adult Wistar rats weighing 250–300 g of either sex were used which were obtained from National Institute of Nutrition, Hyderabad, Andhra Pradesh, India. Animals were housed in groups of 6–7 in colony cages at an ambient temperature of 25 ± 2 °C and 45–55% relative humidity with 12 h light/dark cycle. They had free access to pellet

chow (Pranav Agro Limited) and water ad libitum. As pyrimidines (AUCP1 and AUCP2) are very sparingly soluble in aqueous solutions, to solubilize these compounds, 99% dimethyl sulphoxide (DMSO) was used as vehicle and different concentrations (5 mg/kg, 10 mg/kg, 20 mg/kg and 30 mg/kg) were prepared by dissolving in 50% DMSO and administered intraperitoneally 10 min before reperfusion. At the end of the experiment the brain was removed and used for quantification of infarct size using 2,3,5-triphenyltetrazolium chloride (TTC) staining method. Cerebral infarction was induced by bilateral common carotid artery (BCA) occlusion method described by Iwasaki et al.18 Pyrimidines (AUCP1 and AUCP2) were administered by 15 days pre-treatment at doses of 5, 10, 20 and 30 mg/kg intraperitoneally.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>